Our Product (R8)

Designed for Simplicity

Designed for Everyday

Our Technology

Single-Use, Pre-Loaded Dry Powder Inhaler

Breaking Down Barriers to Care

Barrier to Care for Marketed Devices^†

Patients may delay or avoid using auto-injector devices due to fear of needles.^1.2
Currently approved products may take 20-30 minutes to reach peak epinephrine absorption^3,4
Common storage locations can exceed recommended storage conditions (20 – 25°C)^5-8
Auto-injector devices require replacement every 12 – 24 months due to expiry⁹.

Design Features^*

Simple, needle-free delivery.
Rapid epinephrine absorption.
Suitable for everyday storage.
Extended shelf-life.

*Based on current development objectives and subject to regulatory review and approval.

†Current as of 16th July 2026., ¹Brooks et al., (2017)., ²Alsbrooks & Hoerauf. (2022)., ³ARS Pharmaceuticals, Inc. (2023)., ⁴De Motu Cordis Pty. Ltd. (Unpublished Clinical Study Report). (2023)., ⁵Rachid et al., (2015)., ⁶Warren et al., (2018)., ⁷Rachid et al., (2016)., ⁸Dadour et al., (2011)., ⁹Fineman et al., (2013)

Clinical Studies

Doctor showing a tablet to a mother and her son in a clinic room

First-in-Human Phase 1 Bioavailability Clinical Study completed in 2022
Pilot Venom Challenge Study completed in 2026

Patient Feedback

“I am needle-phobic and in the past have hesitated injecting myself.
I felt less fear inhaling this adrenaline.”

“Felt in control and was happy to use.”

“Reduced my fear level and I felt an increased sense of control,
with this gentle delivery method.”

Developing an epinephrine inhaler for use in anaphylaxis treatment.